Epilepsy Alliance America Announces Seizure ID Program
Baton Rouge, LA: Epilepsy Alliance America announced today that it will be providing 3,000 Seizure ID products to people with epilepsy who need them through a one-of-a-kind campaign in the epilepsy community.
The Seizure ID Program is an initiative promoting safety and independence for patients with epilepsy. The program will allow doctors and first responders treating a patient to have access to their medical profile through a QR code. First responders will be able to access medical profiles within seconds, including the patient’s emergency contact information, as well as doctors who can clearly reference their records on the spot.
The Seizure ID program is made possible through a partnership with Greenwich Pharmaceuticals, now part of Jazz Pharmaceuticals.
Individuals with epilepsy are eligible to receive a $25.00 coupon to be used at www.getmyid.com where they can purchase a Seizure ID wristband or other product of their choice ranging from bracelets, tags, wallet cards and stickers. Individuals with epilepsy can request their coupon code here.
Epilepsy Alliance America is a nation-wide network of community-based epilepsy organizations dedicated to confronting the challenges created by seizures through the promotion of independence and quality of life for people with epilepsy and their families. The member organizations will be promoting this program to their constituents to take advantage of this opportunity.
Greenwich Biosciences, now part of Jazz Pharmaceuticals, is the proud sponsor of Epilepsy Alliance America’s Seizure ID program. The company is the U.S. leader in the field of cannabinoid prescription medicines, and its lead product, EPIDIOLEX® (cannabidiol) oral solution, is approved for the treatment of seizures associated with Lennox Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. The company worked with Epilepsy Alliance America in 2020 to launch Seizures Are Signs, a website for families who are navigating uncontrolled seizures. The site provides an assessment tool that creates a customized doctor discussion guide, educational information, stories from families who have found a diagnosis, resources, links to advocacy groups, and more.
About the Epilepsy Alliance America
Epilepsy Alliance America is a nation-wide network of community-based epilepsy organizations who are dedicated to confronting the spectrum of challenges created by seizures through the promotion of independence and quality of life for people with epilepsy and their families. Epilepsy Alliance America was founded in 2018 by eight leading grassroots epilepsy organizations who have unified in their mission to provide direct support to people with epilepsy, and the people who care for them. Members of Epilepsy Alliance America have been collectively supporting people with epilepsy for decades through support services, information, education, advocacy, and public awareness. As a result, the Alliance provides real epilepsy help to approximately 1 million Americans living with Epilepsy.
Epilepsy Alliance is actively accepting new members who share in our mission of supporting people with epilepsy and their families. Learn more at https://www.epilepsyallianceamerica.org/membership/benefits/. For more information, visit the Epilepsy Alliance America website at www.epilepsyallianceamerica.org
About Greenwich Biosciences and Jazz Pharmaceuticals
Greenwich Biosciences is now part of Jazz Pharmaceuticals, a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. Together we are continuing our commitment to patients and pursuing innovative and differentiated therapies that establish new or better standards of care in neuroscience and oncology. We actively explore new options for patients including novel compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. For more information, please visit www.jazzpharmaceuticals.com.